SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Germano Geno J

(Last) (First) (Middle)
5 GIRALDA FARMS

(Street)
MADISON NJ 07940

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
WYETH [ WYE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Pres.-US Pharm. & Wom. Health.
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2009
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2009 D 23,000(1) D $49.58(2) 20,556.8849(3) D
Common Stock 10/15/2009 D 20,556.8849(3) D (4) 0 D
Common Stock 10/15/2009 D 1,530.974(3) D (4) 0 I By reporting person as PUTMA custodian for children
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units (5) 10/15/2009 D 1,929.16(6) (5) (5) Common Stock 1,929.16 (5) 0 I SESP(6)
Employee Stock Option $56.5938 10/15/2009 D 18,000 (7) (7) Common Stock 18,000 $0.00(7) 0 D
Employee Stock Option $56.525 10/15/2009 D 20,000 (7) (7) Common Stock 20,000 $0.00(7) 0 D
Employee Stock Option $60.705 10/15/2009 D 22,000 (7) (7) Common Stock 22,000 $0.00(7) 0 D
Employee Stock Option $34.675 10/15/2009 D 1 (7) (7) Common Stock 1 $14.905(7) 0 D
Employee Stock Option $41.05 10/15/2009 D 20,000 (7) (7) Common Stock 20,000 $8.53(7) 0 D
Employee Stock Option $40.22 10/15/2009 D 36,000 (7) (7) Common Stock 36,000 $9.36(7) 0 D
Employee Stock Option $43.57 10/15/2009 D 30,000 (7) (7) Common Stock 30,000 $6.01(7) 0 D
Employee Stock Option $48.22 10/15/2009 D 30,000 (7) (7) Common Stock 30,000 $1.36(7) 0 D
Employee Stock Option $56 10/15/2009 D 40,000 (7) (7) Common Stock 40,000 $0.00(7) 0 D
Employee Stock Option $44.56 10/15/2009 D 50,000 (7) (7) Common Stock 50,000 $5.02(7) 0 D
Explanation of Responses:
1. Represents restricted stock units.
2. Pursuant to the Agreement and Plan of Merger by and among Wyeth, Pfizer Inc. and Wagner Acquisition Corp., dated as of January 25, 2009 (as amended, the "Merger Agreement"), each restricted stock unit was cancelled at the effective time of the merger in exchange for cash equal to the per share value of the merger consideration of $49.58, less any applicable tax withholding.
3. Represents Wyeth common stock.
4. Pursuant to the Merger Agreement, each of these shares was cancelled at the effective time of the merger and converted into the right to receive $33.00 in cash and 0.985 of a share of Pfizer Inc. common stock, less any applicable tax withholding.
5. Pursuant to the Merger Agreement, each phantom stock unit in the Supplemental Employee Savings Plan ("SESP") was converted at the effective time of the merger into the the right to receive an amount equal to notional $33.00 in cash plus 0.985 of a phantom share of Pfizer Inc. common stock in accordance with the SESP.
6. Represents phantom stock units in the SESP.
7. Pursuant to the Merger Agreement, each outstanding and unexercised option, whether vested or unvested, was cancelled at the effective time of the merger in exchange for cash equal to the product of (a) the number of shares underlying such option and (b) the excess, if any, of the per share value of the merger consideration of $49.58 over the per share exercise price of the option, less any applicable tax withholding.
Remarks:
Tara J. Gabbai, Attorney-in-Fact for Geno J. Germano 10/19/2009
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.